Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 16/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15531936 | 0.94 | HPRT1 (0.52) | HPRT1FDPSFGFR1FGFR4 | |
| SCHEMBL16617509 | 0.91 | FDPS (0.46) | HPRT1FDPSFGFR1FGFR4CYP1A2 | |
| SCHEMBL16625380 | 0.90 | HPRT1 (0.50) | HPRT1FDPSFGFR1FGFR4CYP1A2 | |
| SCHEMBL16625382 | 0.90 | FDPS (0.43) | HPRT1FDPSFGFR1FGFR4CYP1A2 | |
| SCHEMBL16625367 | 0.88 | HPRT1 (0.54) | HPRT1 | |
| SCHEMBL15553585 | 0.86 | FDPS (0.40) | HPRT1FDPSFGFR1FGFR4CYP1A2 | |
| SCHEMBL16625376 | 0.85 | FDPS (0.46) | HPRT1FDPSFGFR1FGFR4HDAC6 | |
| SCHEMBL15532359 | 0.84 | HPRT1 (0.58) | HPRT1FDPSFGFR1FGFR4HDAC6 | |
| SCHEMBL16625397 | 0.84 | FDPS (0.42) | HPRT1FDPSFGFR1FGFR4CYP1A2 | |
| SCHEMBL16625401 | 0.84 | HPRT1 (0.75) | HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847201-B1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | UNIV QUEENSLAND (AU) | 2017-08-16 | — | — | EP | disclosed |
| US-9200020-B2 | 6-oxopurine phosphoribosyltransferase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-9200020-B2 | 6-oxopurine phosphoribosyltransferase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-20150099722-A1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-04-09 | — | — | US | disclosed |
| US-20150099722-A1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099722-A1 | 6-OXOPURINE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | HPRT1, APRT, TPMT | HPRT1 1/4885FDPS 485/4885FGFR1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.